Results 51 to 60 of about 49,935 (237)
Tofacitinib: raising awareness of mycoses
, 2019 There have been significant therapeutic advances for autoimmune diseases with the development of novel agents targeting inflammatory mediators of the immune system.
Jane Dyer +5 more
core +1 more source
Arthritis Care &Research, Accepted Article.Objective To characterize the prevalence and correlates of dietary supplement use, identify commonly used supplements, and evaluate potential supplement–medication interactions among adults with systemic lupus erythematosus (SLE). Methods We analyzed cross‐sectional data from 451 adults in the Approaches to Positive, Patient‐centered Experiences of ...
Sarah L. Patterson +7 more
wiley +1 more source
Advanced Science, EarlyView.AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Duoli Xie +14 more
wiley +1 more source
ACR Open Rheumatology, 2021 Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease ...
Joel M. Kremer +14 more
doaj +1 more source
Tofacitinib versus methotrexate in rheumatoid arthritis [PDF]
, 2014 Background : Methotrexate is the most frequently used first-line antirheumatic drug. We report the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared with methotrexate monotherapy in patients with ...
Zwillich, Samuel H +23 more
core +1 more source
Advanced Science, EarlyView.An advanced, long‐term human skin platform maintains native skin structure and key tissue functions for up to four weeks. The platform models chronic inflammation, aging‐related skin changes, and UVB damage, enabling drug and topical interventions—including anti‐inflammatory therapy, senolytic treatment, and sunscreen—to be evaluated in intact human ...
Purnendu Kumar Sharma +14 more
wiley +1 more source
Rheumatology and Therapy, 2023 Introduction Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Using mediation modelling, we describe interrelationships between fatigue, pain, morning stiffness, C-reactive protein (CRP) and tofacitinib ...
Lars Erik Kristensen +7 more
doaj +1 more source
Synthesis and evaluation of hydrogen peroxide sensitive tofacitinib prodrugs
European Journal of Medicinal Chemistry Reports, 2022 Tofacitinib (CP-690,550), an approved Janus kinase (JAK) inhibitor, has been proven highly efficacious in treating rheumatoid arthritis (RA). Unfortunately, tofacitinib's clinical application has been limited by adverse side effects that arise from its ...
Viola Previtali +8 more
doaj +1 more source
Annals of Gastroenterological Surgery, EarlyView.ABSTRACT Inflammatory bowel disease management has undergone a major transformation with the introduction of treat‐to‐target strategies and highly effective biologic and small‐molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative ...
Yoshiki Okita +4 more
wiley +1 more source
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis [PDF]
, 2017 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.
Julian Panés +35 more
core +2 more sources